Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Targeting TP53 mutated myelodysplastic syndromes and acute myeloid leukemia remains a significant unmet need. Recently, new drugs have attempted to improve the outcomes of this poor molecular subgroup. The aim of this article is to review all the current knowledge using active agents including hypom...

Descripción completa

Detalles Bibliográficos
Autores principales: Cluzeau, Thomas, Loschi, Michael, Fenaux, Pierre, Komrokji, Rami, Sallman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471083/
https://www.ncbi.nlm.nih.gov/pubmed/34576266
http://dx.doi.org/10.3390/ijms221810105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471083/
https://www.ncbi.nlm.nih.gov/pubmed/34576266
http://dx.doi.org/10.3390/ijms221810105

Ejemplares similares